Omega-3 polyunsaturated fatty acids in the prevention of relapse in patients with stable bipolar disorder: A 6-month pilot randomized controlled trial.
Halliru ZailaniSuet-Kei WuKai-Jie YangIkbal Andrian MalauHsien-Feng LiaoYi-Lun ChungJane Pei-Chen ChangWei-Che ChiuKuan-Pin SuPublished in: Psychiatry research (2023)
This study investigated the efficacy and safety of omega-3 polyunsaturated fatty acids (n-3 PUFAs) in relapse prevention of bipolar disorder (BD), addressing the shortcomings of current medications. Thirty-one stable BD patients were randomized to receive n-3 PUFAs or placebo for 6 months and intergroup differences in the incidence of the recurrence of bipolar depression were assessed. Differences in depression severity, manic symptoms, and routine biochemical parameters were also assessed. Interestingly, n-3 PUFAs demonstrated a favorable preventive effect on bipolar depression recurrence (p=0.005; Log-Rank) and reduced depression severity compared to placebo, and were well-tolerated, suggesting their potential as a safe prophylactic therapy for BD.
Keyphrases
- bipolar disorder
- major depressive disorder
- depressive symptoms
- sleep quality
- randomized controlled trial
- double blind
- free survival
- end stage renal disease
- phase iii
- placebo controlled
- study protocol
- newly diagnosed
- chronic kidney disease
- ejection fraction
- open label
- clinical trial
- peritoneal dialysis
- prognostic factors
- high resolution
- patient reported outcomes